FY2022 Earnings Forecast for Allogene Therapeutics, Inc. Issued By HC Wainwright (NASDAQ:ALLO)

Allogene Therapeutics, Inc. (NASDAQ:ALLOGet Rating) – Research analysts at HC Wainwright upped their FY2022 earnings per share estimates for Allogene Therapeutics in a report released on Monday, November 21st. HC Wainwright analyst R. Burns now anticipates that the company will earn ($2.44) per share for the year, up from their previous forecast of ($2.46). HC Wainwright has a “Buy” rating and a $29.00 price objective on the stock. The consensus estimate for Allogene Therapeutics’ current full-year earnings is ($2.38) per share. HC Wainwright also issued estimates for Allogene Therapeutics’ Q4 2022 earnings at ($0.77) EPS and FY2023 earnings at ($3.00) EPS.

Allogene Therapeutics (NASDAQ:ALLOGet Rating) last announced its quarterly earnings data on Wednesday, November 2nd. The company reported ($0.58) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.62) by $0.04. Allogene Therapeutics had a negative return on equity of 37.74% and a negative net margin of 126,580.16%. During the same quarter in the previous year, the company earned ($0.57) EPS.

ALLO has been the topic of several other research reports. JMP Securities restated a “buy” rating and set a $23.00 price objective on shares of Allogene Therapeutics in a research note on Tuesday, September 27th. B. Riley dropped their price target on Allogene Therapeutics from $21.00 to $18.00 and set a “buy” rating on the stock in a research report on Thursday, September 22nd. Oppenheimer dropped their price target on Allogene Therapeutics to $32.00 in a research report on Thursday, October 13th. Truist Financial dropped their price target on Allogene Therapeutics to $29.00 in a research report on Tuesday, August 23rd. Finally, Raymond James cut Allogene Therapeutics from an “outperform” rating to a “market perform” rating in a research report on Wednesday, August 10th. Two analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $25.70.

Allogene Therapeutics Stock Down 0.9 %

Shares of NASDAQ ALLO opened at $10.60 on Wednesday. The stock’s 50 day moving average price is $10.50 and its two-hundred day moving average price is $11.42. Allogene Therapeutics has a 52-week low of $6.43 and a 52-week high of $19.25. The stock has a market capitalization of $1.53 billion, a P/E ratio of -4.82 and a beta of 0.59.

Hedge Funds Weigh In On Allogene Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. BlackRock Inc. grew its holdings in Allogene Therapeutics by 2.6% in the 3rd quarter. BlackRock Inc. now owns 8,212,580 shares of the company’s stock worth $88,696,000 after buying an additional 207,414 shares in the last quarter. State Street Corp grew its holdings in Allogene Therapeutics by 78.5% in the 1st quarter. State Street Corp now owns 7,877,648 shares of the company’s stock worth $71,765,000 after buying an additional 3,464,603 shares in the last quarter. Price T Rowe Associates Inc. MD grew its holdings in Allogene Therapeutics by 6.3% in the 3rd quarter. Price T Rowe Associates Inc. MD now owns 5,907,316 shares of the company’s stock worth $63,800,000 after buying an additional 348,140 shares in the last quarter. Woodline Partners LP boosted its stake in Allogene Therapeutics by 1,255.9% during the 2nd quarter. Woodline Partners LP now owns 5,859,679 shares of the company’s stock valued at $66,800,000 after purchasing an additional 5,427,529 shares in the last quarter. Finally, Primecap Management Co. CA boosted its stake in Allogene Therapeutics by 5.2% during the 1st quarter. Primecap Management Co. CA now owns 4,906,266 shares of the company’s stock valued at $44,696,000 after purchasing an additional 244,451 shares in the last quarter. 84.81% of the stock is owned by institutional investors.

Allogene Therapeutics Company Profile

(Get Rating)

Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL.

Featured Articles

Earnings History and Estimates for Allogene Therapeutics (NASDAQ:ALLO)

Receive News & Ratings for Allogene Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allogene Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.